Table 3.
Synergistic effect of Erlotinib and GLE in cells with Erlotinib resistance.
| Constant ratio | |||||||||||||
| Combination Indices | |||||||||||||
| Treatment | Cell line | ED50 | ED75 | ED90 | ED95 | Dm | |||||||
| Erl+GLE | rSUM-149 | 0.75667 | 1.44933 | 2.77615 | 4.31960 | 0.25833 | |||||||
| MDA-MB-231 | 0.21779 | 0.25714 | 0.30388 | 0.34043 | 0.07729 | ||||||||
| Erl (μM) | rSUM-149 | 31.7139 | |||||||||||
| MDA-MB-231 | 8.0631 | ||||||||||||
| GLE (mg/mL) | rSUM-149 | 0.32788 | |||||||||||
| MDA-MB-231 | 0.34782 | ||||||||||||
| Non-constant ratio | |||||||||||||
| rSUM-149 | MDA-MB-231 | ||||||||||||
| Dose Erl (μM) | Dose GLE (mg/mL) | Effect | CI | Description | Effect | CI | Description | ||||||
| 0.06 | 0.2 | 0.31276 | 1.31749 | MA | 0.31276 | 1.58155 | A | ||||||
| 0.13 | 0.42259 | 0.83210 | MS | 0.42259 | 0.85996 | SlS | |||||||
| 0.25 | 0.38245 | 0.98438 | AE | 0.38245 | 1.23073 | MA | |||||||
| 0.50 | 0.35481 | 1.11712 | SlA | 0.35481 | 2.08423 | A | |||||||
| 1.00 | 0.41835 | 0.88125 | SlS | 0.41835 | 1.38702 | MA | |||||||
| 2.00 | 0.41595 | 0.93012 | SlS | 0.41595 | 2.03295 | A | |||||||
| 4.00 | 0.39130 | 1.11283 | SlA | 0.39130 | 4.85018 | StA | |||||||
| 8.00 | 0.53760 | 0.75249 | MS | 0.53760 | 0.98228 | AE | |||||||
A=Antagonism, AE=Additive Effect, MA=Moderate Antagonism, MS=Moderate Synergism, SlA=Slight Antagonism, SlS=Slight Synergism, StA=Strong Antagonism.